Ranjit Bindra

Company: Modifi Bio

Job title: Co-Founder

Seminars:

Targeted DNA Modification: A New Paradigm to Exploit DDR Defects in Glioma and Beyond… 3:30 pm

Discuss Modifi Bio’s development candidate which selectively targets MGMT-deficient cancers Review data suggesting efficacy of these molecules across a range of brain tumor models, as a monotherapy and in combination with other agents Highlights of Modifi’s biomarker strategy to enrich for MGMT- gliomas with acquired MMR mutations in a phase 0/I trialRead more

day: Conference Day 2